BioLineRx Announces Issuance of United States Patent Covering Use of BKT-140/BL-8040 in Immunotherapy
BKT-140/BL-8040 is currently undergoing a Phase 2 trial for acute myeloid leukemia (AML) and is expected to commence a Phase 1 trial in stem cell mobilization in Q2 2014.